

Dmitry A Zateyshchikov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/988294/dmitry-a-zateyshchikov-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

28,239
citations

44
h-index

149
g-index

149
ext. papers

34,570
ext. citations

9.2
avg, IF

6.54
L-index

#	Paper	IF	Citations
108	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 584-595	0.9	0
107	Molecular cardiology: from decoding the genetic nature and mechanisms of the diseases development to the introduction into the clinic. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 463-466	0.9	
106	Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 11-15	0.5	
105	Pitavastatin: focus on safety and drug interactions. <i>Cardiosomatics</i> , 2021 , 12, 48-53	0.4	
104	Visit-to-visit blood pressure variability in patients after acute coronary syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2021 , 27, 206-215	0.7	
103	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021 , 42, 3063-3073	9.5	8
102	Prevalence of hereditary factors in different age groups in patients with acute coronary syndrome. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2021 , 27, 281-290	0.1	
101	CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. <i>Pharmacogenomics Journal</i> , 2020 , 20, 687-694	3.5	5
100	Bleeding risk scales in patients with acute coronary syndrome: place of the ORACUL scale. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020 , 19, 2333	0.9	
99	RESULTS OF MULTICENTER MONITORING OF HEMOSTASIS PARAMETERS IN PATIENTS WITH COVID-19. <i>Pediatria</i> , 2020 , 99, 62-73	1.5	2
98	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
97	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 1309-1320	59.2	156
96	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. <i>JAMA Cardiology</i> , 2019 , 4, 526-548	16.2	13
95	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2780-2782	15.1	19
94	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019 , 213, 35-46	4.9	28
93	Physicians Sguideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 921-929	12.3	53
92	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019 , 42, 498-505	3.3	19

91	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
90	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019 , 132, 1431-1440.e7	2.4	5
89	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5). <i>Russian Journal of Cardiology</i> , 2019 , 92-97	1.3	1
88	Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II. <i>Russian Journal of Cardiology</i> , 2019 , 24, 7-16	1.3	4
87	A clinical case of hypertrophic cardiomyopathy and family hyperlipidemia. <i>Journal of Clinical Practice</i> , 2019 , 10, 97-101	0.4	
86	Lipidome features in patients with different probability of family hypercholesterolemia. <i>Bulletin of Russian State Medical University</i> , 2019 , 84-91	0.4	
85	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 2331-2341	5	3
84	VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND RISK OF ALL-CAUSE DEATH. <i>Journal of Hypertension</i> , 2019 , 37, e195	1.9	
83	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 319-327	7	43
82	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. <i>Acta Cardiologica</i> , 2019 , 74, 309-318	0.9	11
81	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019 , 139, 787-798	16.7	39
80	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018 , 39, 464-473	9.5	25
79	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ² trial. <i>European Heart Journal</i> , 2018 , 39, 363-370	9.5	171
78	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018 , 120, 645-656	5.4	99
77	Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME ² . <i>Diabetologia</i> , 2018 , 61, 1522-1527	10.3	33
76	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018 , 137, 119-129	16.7	252
75	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018 , 379, 1118-1127	59.2	143
74	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018 , 13, e0191592	3.7	53

73	Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome. <i>Bulletin of Russian State Medical University</i> , 2018 , 80-86	0.4	5
72	Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. <i>Terapevticheskii Arkhiv</i> , 2018 , 90, 37-41	0.9	0
71	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. <i>Russian Journal of Cardiology</i> , 2018 , 22-27	1.3	
70	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	4.0	204
69	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	4.0	414
68	IL-10 GENE POLYMORPHISM AND STROKE RISK IN PATIENTS WITH CORONARY ARTERY DISEASE. <i>Journal of Hypertension</i> , 2018 , 36, e217	1.9	
67	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF. <i>Circulation Journal</i> , 2018 , 83, 67-74	2.9	9
66	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2755-2769	12.7	81
65	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018 , 70, 828-835	1.6	10
64	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 27-35	4.6	8
63	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017 , 10,	6.4	94
62	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017 , 135, 1273-1275	16.7	94
61	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017 , 103, 307-314	5.1	163
60	Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017 , 7, e014579	3	22
59	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017 , 48, 1218-1225	6.7	86
58	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
57	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1527-1539	59.2	390
56	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017 , 194, 132-140	4.9	104

55	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME. <i>Circulation Journal</i> , 2017 , 81, 227-234	2.9	80
54	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
53	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	14
52	[PP.30.09] KIF6 GENE POLYMORPHISM IS ASSOCIATED WITH ARTERIAL RESISTANCE AND ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION. <i>Journal of Hypertension</i> , 2017 , 35, e333	1.9	
51	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017 , 7, e017157	3	58
50	PRIMARY (GENETICALLY DETERMINED) DILATION CARDIOMYOPATHY IN A PATIENT WITH NOVEL MUTATION OF LAMIN GENE: CLINICAL AND MORPHOLOGICAL MANAGEMENT. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2017 , 16, 76-82	0.9	2
49	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 114-122	4.6	23
48	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016 , 223, 543-547	3.2	62
47	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 323-34	59.2	1956
46	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016 , 174, 610-23	4.5	8
45	A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 861-71	7.4	110
44	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016 , 5, e002197	6	94
43	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016 , 11, e0164076	3.7	90
42	The use of optimal partitionings for multiparameter data analysis in clinical trials. <i>Mathematical Biology and Bioinformatics</i> , 2016 , 11, 46-63	0.5	7
41	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016 , 37, 2882-2889	9.5	167
40	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Stroke</i> , 2016 , 47, 2075-82	6.7	57
39	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016 , 39, 345-6	3.3	46
38	Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, S12-20	5.8	63

37	Late Silent Stent Abscess. <i>Cardiology</i> , 2015 , 132, 65-7	1.6	1
36	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 2117-28	59.2	6064
35	An intuitive risk factors search algorithm: usage of the Bayesian network technique in personalized medicine. <i>Journal of Applied Statistics</i> , 2015 , 42, 71-87	1	7
34	Chronic thromboembolic pulmonary hypertension. <i>Deutsches A&#x0308;rzteblatt International</i> , 2014 , 111, 856-62	2.5	16
33	Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 252-62	27.4	205
32	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1006-15	27.4	285
31	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. <i>Stroke</i> , 2014 , 45, 2372-8	6.7	43
30	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2013 , 369, 2093-104	59.2	3215
29	WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE. <i>Rational Pharmacotherapy in Cardiology</i> , 2012 , 8, 581-586	0.5	
28	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
27	Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. <i>American Heart Journal</i> , 2011 , 161, 1012-23.e3	4.9	13
26	Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and genetic association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease. <i>Russian Journal of Genetics</i> , 2011 , 47, 1234-1239	0.6	1
25	Association of the polymorphic markers G(455)A in the FGB gene and C(1654)T in the PROC gene with hereditary predisposition to unfavourable outcome in patients with history of acute coronary syndrome. <i>Molecular Biology</i> , 2010 , 44, 541-545	1.2	3
24	The polymorphisms G(174)C in IL6 gene and G(1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. <i>Molecular Biology</i> , 2010 , 44, 741-747	1.2	3
23	THE MODERN ASPECTS OF CLOPIDOGREL USE. <i>Rational Pharmacotherapy in Cardiology</i> , 2010 , 6, 185-191	0.5	
22	Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. <i>Journal of Cardiac Failure</i> , 2010 , 16, 25-35	3.3	72
21	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2010 , 376, 517-23	40	184
20	Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. <i>New England Journal of Medicine</i> , 2010 , 363, 1419-28	59.2	407

19	Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. <i>Heart and Vessels</i> , 2010 , 25, 229-36	2.1	30
18	Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 192-9	5.1	9
17	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
16	The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. <i>Journal of Cardiac Failure</i> , 2008 , 14, 631-40	3.3	146
15	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	4.0	775
14	Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. <i>Circulation: Heart Failure</i> , 2008 , 1, 9-16	7.6	90
13	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
12	Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21, 437-43	3.1	18
11	Association of GNB3 gene C825T polymorphism with coronary heart disease. <i>Russian Journal of Genetics</i> , 2007 , 43, 937-941	0.6	1
10	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 354, 1464-76	59.2	922
9	Association of Polymorphic Marker A1/A2 of Gene ITGB3 with Coronary Artery Disease and Myocardial Infarction. <i>Russian Journal of Genetics</i> , 2004 , 40, 1156-1158	0.6	
8	Association of Polymorphic Marker G(455)A of Gene FGB with Coronary Artery Disease. <i>Russian Journal of Genetics</i> , 2004 , 40, 1159-1162	0.6	
7	ASSOCIATION OF THE POLYMORPHIC MARKERS OF MTHFR, EDN1, CYP11B2, PPARA AND PPARG2 GENES WITH THE SEVERITY OF ESSENTIAL HYPERTENSION. <i>Journal of Hypertension</i> , 2004 , 22, S342	1.9	
6	Association of the T174M and M235T Polymorphisms of the Angiotensinogen Gene with Coronary Heart Disease in Ethnic Russians from Moscow. <i>Molecular Biology</i> , 2003 , 37, 52-55	1.2	5
5	Association of the G7831A Polymorphism of the ACE Gene with Coronary Heart Disease in Muscovites. <i>Molecular Biology</i> , 2003 , 37, 49-51	1.2	3
4	Polymorphic Markers at the Genes Encoding the Endothelial NO-Synthase and Angiotensin II Type 1 Receptor and the Susceptibility to Ischemic Heart Disease. <i>Russian Journal of Genetics</i> , 2000 , 36, 1440-1444	0.6	1
3	Anticoagulant properties of the endothelium studied by the standard venous occlusion test. <i>Bulletin of Experimental Biology and Medicine</i> , 1992 , 114, 1804-1808	0.8	
2	Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome. <i>Russian Journal of Cardiology</i> , 2003 , 25, 4023	1.3	1

- 1 Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice. *Russian Journal of Cardiology*, 25, 4024

1.3 0